Article Text
Statistics from Altmetric.com
Zhang et al recently described ACE2 expression along the GI tract and suggests the digestive system as a potential route for COVID-19.1 ACE2 is also expressed in the pancreas2 and lipase elevations, suggestive of pancreatic involvement, have been reported among patients with COVID-19.3 A recent case report4 demonstrated that severe pancreatitis may occur in COVID-19. However, the clinical implications of these findings with regards to COVID-19 susceptibility among patients with prior pancreatitis are unclear.
In this retrospective study, we explored the prevalence, risk factors and outcomes of COVID-19 among patients with a history of pancreatitis. Consecutive patients whose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA testing was performed at Stanford between 4 March 2020, and 14 April 2020 (Institutional Review Board (IRB) protocol 55975) and had a history of acute (K85) or chronic pancreatitis (K86) were included. We performed univariate and multivariate logistic regression to determine …
Footnotes
Twitter @JGubatanMD
Contributors JG and AH planned and designed the study and analysed the data. JG, SL, TB, AP and AS performed the literature review and data extraction in chart reviews. JG performed the statistical analyses, drafted the manuscript and had full access to the study data and takes responsibility for the integrity of the data and accuracy of the analysis. AH, EJ, BL, MM, GS and WP provided critical review of the manuscript. All authors interpreted the results and contributed to critical review of the manuscript.
Funding The study was in part supported by the National Institutes of Health Award U01DK108300 (WGP, AH).
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.